20.6 C
New York
Thursday, June 18, 2026

Tag: month

Best Way to Check and Increase Your Credit Scores (2026): Experian Boost® Named Top Tool for Raising Credit Scores by Expert Consumers

NEW YORK, June 15, 2026 /PRNewswire/ -- Expert Consumers has released a new in depth review highlighting Experian Boost® and its role in helping people...

Two Weeks Remaining to Enter the Global Sustainability Awards 2026

The Global Sustainability Awards 2026 enters its final submission period, with just two weeks remaining to recognise sustainability excellence

Ticketbay Expands Safer Access to K-pop Concert Tickets for Global Fans

Escrow-Based Marketplace Supports Secure Transactions for International UsersSEOUL, South Korea, June 15, 2026 /PRNewswire/ -- International fans traveling to South Korea for K-pop concerts...

CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026

SHANGHAI, June 14, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces poster...

Bambu Lab Store Hits Record-Low Prices — Including First-Ever Discounts on P2S, H2S and H2C

The 4th Anniversary Sale runs June 15 to July 15 across US, EU, UK, Canada, and Australia — with record-low prices on P1S, P2S,...

Bambu Lab Store Hits Record-Low Prices — Including First-Ever Discounts on P2S, H2S and H2C

The 4th Anniversary Sale runs June 15 to July 15 across US, EU, UK, Canada, and Australia — with record-low prices on P1S, P2S,...

ENSG Investor News: If You Have Suffered Losses in Ensign Group, Inc. (NASDAQ: ENSG), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public.

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2...

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

MUSSO E80 Muse Sees Strong U.S. Sales Following European Breakout and MUSE Design Award Win

MUSSO E80 Muse Ergonomic chair for petite women releasing in USA

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

Marler Clark Urges Parents to Stop Using Nara Organics Whole Milk Organic Powdered Infant Formula Amid Multistate Infant Botulism Outbreak — Product Sold Nationwide...

FDA, CDC, and public health officials in California, Pennsylvania, and Washington are investigating; food safety attorney Bill Marler calls it the second formula-linked infant...

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

EpiCooler Product Information Updated As Consumer Interest In Portable AC Grows In 2026

Kaunas, Lithuania, June 13, 2026 (GLOBE NEWSWIRE) --

An informational overview examining EpiCooler Portable AC Product Details, Publicly available product disclosures and what consumers often consider when researching portable cooling devices in 2026

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMonth